Biotechnology, along with machine learning and artificial intelligence, is assisting in making rapid advancements in healthcare. GenepoweRx, a Hyderabad-based health tech start-up, is providing physician-friendly genome reports. They make the best use of artificial intelligence and deep technology to interpret genes and suggest clinical interpretations based on the output.
Human genome sequencing is a process through which individuals can learn about their genetic makeup and disease risk. This knowledge makes them more aware of the potential health issues they might face in the future. This assists in making informed lifestyle choices that further result in the lessening of ailments. Nevertheless, the healthcare industry will also benefit hugely. The genetic reports suggest the right medication based on individual genes. The sequencing technology has ushered the medical world into the Personalized or Precision Medicine era. Consuming medicines based on individual genetic makeup will increase the chances of a better response and cut down on the toxicity caused by the unabsorbed medicine.
Dr.Kalyan Uppaluri, Founder GenepoweRx shares, “DNA sequencing has helped cancer patients greatly and opened avenues for novel and cutting-edge ways to identify and treat cancers. It has also helped in cancer drug development. Every cancer is different. In this aspect, one size does not fit all and highlights that the same chemotherapy may not best suit each cancer patient. We have desgined OncoRx for cancer treatment. We have developed bioinformatics algorithms for data analysis. OncoRx uses targeted genomic sequencing and analysis and provides crucial information to the physicians around druggable mutations in the patients, where targeted therapies are immensely helpful.”
The genetic experts at GenepoweRx interpret clinically generated reports and suggest lifestyle changes or treatments based on that. They provide consultancy in the sphere of oncology, diabetes, hypertension, nutrition, fitness, heart ailments, and many more. The start-up utilizes Memorial Sloan Kettering Cancer Center’s clinical and research insights into gene mutations associated with solid tumors. MSK’s Precision Oncology Knowledge Base is the only FDA-recognized database for 127 cancer types and 108 FDA-approved drugs. MSK is one of the world’s former and largest private cancer centers.
Genome sequencing needs to be done at an authentic lab with proper infrastructure at the back end. The process is simple as it involves taking samples of blood, hair, ammonia fluid, saliva, etc. The important thing here is that an individual should check for the quality of sequencing and analysis of the sequencing results. There are numerous panels of short genes or tests on a single gene that may cost less than Rs. 10,000. The complete sequencing of the exome is often more efficient in terms of cost and time than performing several tests on a single gene or panel. Typically, whole-exome sequencing starts from 45000 to 80,000.
Genome sequencing occupies a precise role among the various genomic test medley in the market. These complex tests make it possible to identify genetic variants linked to a person’s health. GenepoweRx genomic sequencing starts with isolating DNA from the patient’s blood sample. The isolated DNA is sequenced, and the raw data is analyzed. Whole exome sequencing is an all-inclusive genetic test that ascertains changes in a patient’s DNA that are causative or associated with their medical concerns by focusing on the entire protein-coding regions of the genome – the exome.
These test assists in diagnosing a suspected genetic disorder. They are also pre-symptomatic and predictive. In other words, it helps to determine the risk of metabolic disorders, cancers, etc. Also, pharmacogenetic tests help identify the drug and dosage regimen that will be most effective and beneficial to an individual.
Over time Biotechnology will open more gateways, thus will empower the patients to make wise choices around their health.
Please visit – https://genepowerx.com/
(ThePrint ValueAd Initiative content is a paid-for, sponsored article. Journalists of ThePrint are not involved in reporting or writing it.)